A strategy to kill solid tumors in a tissue-agnostic manner
Atengen is developing drugs that target a novel receptor found in the blood vessels of most solid tumors. We are developing a new generation of therapeutics designed to kill tumors by killing tumor blood vessels.
Our target is highly specific; it is only found in tumor blood vessels.
At the same time, our target is very broad; it is present in the tumor blood vessels of most solid tumors.
Kills Tumor Blood Vessels
Our approach disrupts new tumor blood vessel growth that is mediated by multiple different angiogenic factors and results in the death of existing tumor blood vessels.
Suppress and Kill Solid Tumors
Our approach both suppresses tumor growth and kills existing tumors.
Less Susceptible to Mutagenesis
Since we are not targeting cancer cells, our approach is less susceptible to mutagenesis.
Napoleone Ferrara, MD
Dr. Ferrara is a Distinguished Professor at UCSD. He obtained his M.D. from the University of Catania and conducted post-doctoral research at UCSF.
Yihai Cao, MD, PhD
Dr. Cao is a Distinguished Professor of Vascular Biology at Karolinska Institute in Stockholm, Sweden. He received his Ph.D. from the Karolinska Institute and trained with Dr. Judah Folkman at Harvard.
Ernest Wright, PhD, FRS
Dr. Wright is a Distinguished Professor of Physiology and Medicine at UCLA. He received his Ph.D. at University of Sheffield and was trained at Harvard.
Jeremy Nathans, MD, PhD
Dr. Nathans is a Howard Hughes Medical Institute Investigator and Professor at Johns Hopkins School of Medicine. He received his M.D. and Ph.D. degrees from Stanford University.
Steven McKnight, PhD
Dr. McKnight is a Distinguished Professor at UT Southwestern Medical Center. He received his Ph.D. from the University of Virginia and conducted post-doctoral research at the Carnegie Institute of Washington.